The role of drugs in the pathogenesis of gingival overgrowth: A collective review of current concepts

Periodontology 2000

Volumn 21, Issue 1, 1999, Pages 176-196

  Hallmon, William W ^a   Rossmann, Jeffrey A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

CHEMICALLY INDUCED DISORDER; GINGIVA OVERGROWTH; HUMAN; REVIEW;

ANTICONVULSANTS; CALCIUM CHANNEL BLOCKERS; CYCLOSPORINE; GINGIVAL OVERGROWTH; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 0033212104     PISSN: 09066713     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0757.1999.tb00175.x     Document Type: Review

References (185)

1. Aas E. Hypoplasia diphenylhydantoinea. Acta Odontol Scand 1963: 2(suppl 34): 1-132.
2. Adams D, Davies G. Gingival hyperplasia associated with cyclosporine A. Br Dent J 1984: 157: 89-90.
3. Addy V, McElnay J, Eyre D, Campbell N, D'Arcy P. Risk factors in phenytoin-induced gingival overgrowth. J Periodontol 1982: 54: 373-377.
4. Allison MC, Pounder RE. Cyclosporine for Crohn's disease. Lancet 1984: 7: 902-903.
5. Angelopoulos AP. Diphenylhydantoin gingival hyperplasia: a clinico-pathological review. I. Incidence, clinical features and histopathology. J Can Dent Assoc 1975: 41: 103-106.
6. Angelopoulos AP, Goaz PW. Incidence of diphenylhydantoin gingival hyperplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1972: 34: 898-906.
7. Atkinson K, Biggs J, Darveniza P, Boland J, Concannon A, Dodds A. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984: 38: 34-37.
8. Babcock JR. The successful use of a new therapy for Dilantin® gingival hyperplasia. Periodontics 1965: 3: 196-199.
9. Ballard JB, Butler WT. Proteins of the periodontium. Biochemical studies on collagen an non-collagenous proteins of human gingiva. J Oral Pathol 1974: 3: 176-184.
10. Barak S, Engelberg IS, Hiss J. Gingival hyperplasia caused by nifedipine-histological findings. J Periodontol 1987: 58: 639-642.
11. Barclay S, Thomason JM, Idle JR, Seymour RA. The incidence and severity of nifedipine-induced gingival overgrowth. J Clin Periodontol 1992: 19: 311-314.
12. Bartold PM. Regulation of human gingival fibroblast growth and synthetic activity by cyclosporine A in vitro. J Periodontal Res 1989: 24: 314-321.
13. Beveridge T, Gratwohl A, Michot F. Cyclosporine A: pharmacokinetics after a single dose in man and serum levels after multiple dosing in recipients of allogeneic bone marrow grafts. Curr Ther Res 1981: 30: 5-12.
14. Bökenkamp A, Bohnhorst B, Beier C, Albers N, Offner G. Nifedipine aggravates cyclosporin A-induced gingival hyperplasia. Pediatr Nephrol 1994: 8: 181-185.
15. Bonnaure-Mallet M, Tricot-Doleux S, Godeau G. Changes in extracellular matrix macromolecules in human gingiva after treatment with drugs inducing gingival overgrowth. Arch Oral Biol 1995: 40: 393-100.
16. Bowman JM, Levy BA, Grubb RV. Gingival overgrowth induced by diltiazem. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1988: 65: 183-185.
17. 2+ accumulation in gingival fibroblasts in vitro. J Oral Pathol Med 1989: 18: 485-489.
18. Bredfeldt GW. Phenytoin-induced hyperplasia found in edentulous patients. J Am Dent Assoc 1992: 123: 61-64.
19. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. J Oral Pathol Med 1991: 20: 201-209.
20. Brown RS, Diástanislao PT, Beaver WT, Bottomley WK. The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1991: 71: 565-568.
21. Brown RS, Sein P, Corio R, Bottemley W. Nitrendipine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1990: 70: 593-596.
22. Bullon P, Machuca G, Martinez-Sahquillo A, Rios J, Rojas J, Lacalle J. Clinical assessment of gingival hyperplasia in patients treated with nifedipine. J Clin Periodontol 1994: 21: 256-259.
23. Bullon P, Machuca G, Martinez-Sahquillo A, Rojas J, Lacalle J, Rios J, Velasco E. Clinical assessment of gingival size among patients treated with diltiazem. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995: 79: 300-304.
24. Butler RT, Kalkwarf KL, Kaldahl WB. Drug-induced gingival hyperplasia: phenytoin, cyclosporine, and nifedipine. J Am Dent Assoc 1987: 114: 56-60.
25. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Henderson R, Hamilton DL, Boone N, McMaster P, Gibby O, Williams R. Cyclosporine A in clinical organ grafting. Transplant Proc 1981: 13: 349-358.
26. Calne RY, Thiru S, McMaster P, Cradock GN, White DJG, Evans DB, Dunn DC, Pentlow BD, Rolles K. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978: 1: 1323-1327.
27. Cebeci I, Kantarci A, Firatli E, Carin M, Tuncer O. The effect of verapamil on the prevalence and severity of cyclosporine-induced gingival overgrowth in renal allograft recipients. J Periodontol 1996: 67: 1201-1205.
28. Church LF Jr, Brandt SK. Phenytoin-induced gingival overgrowth resulting in delayed eruption of the primary dentition. A case report. J Periodontol 1984: 55: 19-21.
29. Ciancio SG, Yaffe ST, Catz CC. Gingival hyperplasia and diphenylhydantoin. J Periodontol 1972: 43: 411-414.
30. Cockey G, Broughman J, Hassell T. Phenytoin response of gingival fibroblasts from human twins. J Dent Res 1987: 66: 320.
31. Coley C, Jarvis K, Hassell T. Effect of cyclosporine A on human gingival fibroblasts in vitro. J Dent Res 1986: 65: 353 (abstr 1658).
32. Colvard MD, Bishop J, Weissman D, Gargiulo A. Cardizem-induced gingival hyperplasia: Report of two cases. Periodontal Case Rep 1986: 8: 67-68.
33. Dahllöf F, Axio E, Modéer T. Regression of phenytoin-induced gingival overgrowth after withdrawal of medication. Swed Dent J 1991: 15: 139-143.
34. Dahllöf G, Modéer T. The effect of a plaque control program on the development of phenytoin-induced gingival overgrowth. A 2-year longitudinal study. J Clin Periodontol 1986: 13: 845-849.
35. Dahllöf G, Modéer T, Reinhart FP, Wikström B, Hjerpe A. Proteoglycans and glycosaminoglycans in phenytoin-induced gingival overgrowth. J Periodontal Res 1986: 21: 13-21.
36. Dahllöf G, Reinholt FP, Hjerpe A, Modéer T. A quantitative analysis of connective tissue components in phenytoin-induced gingival overgrowth in children. J Periodontal Res 1984: 19: 401-407.
37. Daley TD, Wysocki GP, May C. Clinical and pharmacological correlations in cyclosporine-induced gingival hyperplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1986: 62: 417-421.
38. Davis RK, Baer PN, Palmer JH. A preliminary report on a new therapy for Dilantin® gingival hyperplasia. J Periodontol 1963: 34: 17-22.
39. De Camargo PM. Cyclosporine and nifedipine-induced gingival enlargement: an overview. J Western Soc Periodontol 1989: 37: 57-64.
40. Dill RE, Miller K, Weil T, Lesley S, Farmer G, Iacopino A. Phenytoin increases gene expression for platelet-derived growth factor B chain in macrophages and monophages. J Periodontol 1993: 64: 169-173.
41. Dongari A, McDonnell HT, Langals RP. Drug-induced gingival overgrowth. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1993: 76: 543-548.
42. Drew HJ, vogel RI, Molofsky W, Baker H, Frank O. Effect of folate on phenytoin hyperplasia. J Clin Periodontol 1987: 14: 350-356.
43. Dreyer WP, Dent HD, Thomas CJ. Diphenylhydantoin hyperplasia of the masticatory mucosa in an edentulous epileptic patient. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1978: 45: 701-706.
44. Drug and information for the health care professional, Volume I, 17th edn. Taunton, MA: Rand McNally, USPDI, 1997: 680-695.
45. Eeg-Olofsson O, Lundstrom A, Hamp SE. Oral state of children with epilepsy on treatment with sodium valproate. Scand J Dent Res 1983: 91: 219-223.
46. Ellis JS, Seymour RA, Monkman SC, Idle JR. Gingival sequestration of nifedipine in nifedipine-induced gingival overgrowth. Lancet 1992: 339: 1382-1383.
47. Ellis JS, Seymour RA, Monkman SC, Idle JR. Desposition of nifedipine in plasma and gingival crevicular fluid in relation to drug-induced gingival overgrowth. J Periodontal Res 1993: 28: 373-378.
48. Fattore L, Stableirn M, Brenfeldt G, Semla T, Moran B, Doherty-Greenberg JM. Gingival hyperplasia: a side effect of nifedipine and diltiazem. Spec Care Dent 1991: 11: 107-109.
49. Friskopp J, Klintmalm G. Gingival enlargement: a comparison between cyclosporine and azathioprine treated renal allograft recipients. Swed Dent J 1986: 10: 85-92.
50. Fuiano G, Pacchiano G, Lotito MA, Vaia E, Matarasso S, Andreucci VE. Relation of gingival hypertrophy and blood vessels of cyclosporine A in patients with renal transplants. Ann Ital Med Int 1989: 4: 161-166.
51. Fujii A, Matsumoto H, Nakao S, Teishigawara H, Akimoto Y. Effect of calcium channel blockers on cell proliferation, DNA synthesis and collagen synthesis of cultured gingival fibroblasts derived from human nifedipine responders and non-responders. Arch Oral Biol 1994: 39: 99-104.
52. Giustiani S, Robertelli della Cuna F, Marieni M. Hyperplastic gingivitis during diltiazem therapy. Int J Cardiol 1987: 15: 247-249.
53. Goultschin J, Sofer B, Shoshaw S. The effect of prolonged phenytoin administration of non-collagenous components of gingival tissue. Int J Tissue React 1983: 2: 227-230.
54. Graffenried B von, Krupp P. Side-effects of cyclosporine (Sandimmune) in renal transplant recipients and in patients with autoimmune diseases. Transplant Proc 1986: 18: 876-883.
55. Gupta S, Keshavarzian A, Hodgson HJF. Cyclosporine in ulcerative colitis. Lancet 1984: 7: 1277-1278.
56. Hall WB. Dilantin® hyperplasia: a preventable lesion? Compendium Contin Educ Dent 1990: 11(suppl 14): S502-S505.
57. Hamilton DV, Carmichael DJS, Evans DB, Calne RY. Hypertension in renal transplant recipients in cyclosporine A and corticosteroids and azathioprine. Transplant Proc 1982: 13: 597-600.
58. Hancock R, Swan R. Nifedipine-induced gingival overgrowth. J Clin Periodontol 1992: 19: 12-14.
59. Hassell T. Epilepsy and the oral manifestations of phenytoin therapy. Monogr Oral Sci 1981: 9: 1-205.
60. Hassell T. Stimulation and inhibition of fibroblast subpopulations by phenytoin and phenytoin metabolites: Pathogenic role in ginvial enlargement. Pediatr Dent 1981: 3: 137-153.
61. Hassell T. Evidence for production of an inactive collagenase by fibroblasts from phenytoin-enlarged human gingivae. J Oral Pathol 1982: 11: 310-317.
62. Hassell T. Gingival overgrowth: Hereditary considerations. Compendium Contin Educ Dent 1990: 11(suppl 14): S511-S514.
63. Hassell TM, Buchanan J, Cuchens M, Douglas R. Fluorescence activated vital cell sorting of human fibroblast subpopulations that bind cyclosporine A. J Dent Res 1988: 67: 273.
64. Hassell T, Burtner AP, McNeal D, Smith RG. Oral problems and genetic aspects of individuals with epilepsy. Periodontol 2000 1994: 6: 68-78.
65. Hassell T, Gilbert G. Phenytoin sensitivity of fibroblasts as the basis for susceptibility to gingival enlargement. Am J Pathol 1983: 112: 218-223.
66. Hassell T, Harris E, Boughman J, Cockey G. Gingival overgrowth: hereditary considerations. Compendium Contin Educ Dent 1990: 11:(suppl 14): S511-S514.
67. Hassell TM, Hefti AF. Drug-induced gingival overgrowth: old problem, new problem. Crit Rev Oral Pathol Med 1991: 2: 103-137.
68. Hassell T, O'Donell J, Pearlman J, Tesini D, Murphy T, Best H. Phenytoin-induced gingival overgrowth in institutionalized epileptics. J Clin Periodontol 1984: 11: 242-253.
69. Hassell T, Page R. The major metabolite of phenytoin (Dilantin®) induces gingival overgrowth. J Periodontal Res 1978: 13: 21B: 280-282.
70. Hassell T, Page R, Narayangan A, Cooper C. Diphenylhydantoin (Dilantin®) gingival hyperplasia: drug-induced abnormality of connective tissue. Proc Natl Acad Sci U S A 1976: 73: 2909-2912.
71. Hefti AF, Eshenaur AE, Hassell TM, Stone C. Gingival overgrowth in cyclosporine A treated multiple sclerosis patients. J Periodontol 1994: 65: 744-749.
72. Heijl L, Sundin Y. Nitrendipine-induced gingival overgrowth in dogs. J Periodontol 1988: 60: 104-112.
73. Henskens YMC, Strooker H, Van den Keijbus P, Verrman EC, Nieuw AM, Amerongen AV. Salivary protein composition in epileptic patients on different medications. J Oral Pathol Med 1996: 25: 360-366.
74. Iacopino AM, Doxey D, Cutler CW, Nares S, Stoever K, Foj TJ, Gonzales A, Dill RE. Phenytoin and cyclosporine A specifically regulate macrophage and expression of platelet-derived growth factor and interleukin-1 in vitro and in vivo: possible mechanism of drug-induced overgrowth. J Periodontol 1997: 68: 73-83.
75. Ishida H, Rondoh T, Kataoka M, Nishikawa S, Nakagawa T, Morisake I, Rido J, Oka T, Nagata T. Factors influencing nifedipine-induced gingival overgrowth in rats. J Periodontol 1995: 66: 345-350.
76. Jacobs D, Buchanan J, Cuchens M, Hassell TM. The effect of cyclosporine metabolite OL-17 on gingival fibroblast subpopulations. J Dent Res 1990: 69: 221.
77. Johnson BD, Narayanan AS, Preters HP, Page RC. The effect of cell donor age on the synthetic properties of fibroblasts obtained from phenytoin-induced hyperplasia. J Periodontal Res 1990: 25: 74-80.
78. Jones JE, Weddell JA, McKown CG. Incidence and indications for surgical management of phenytoin-induced gingival overgrowth in a cerebral palsy population. J Oral Maxillofac Surg 1988: 46: 385-390.
79. Jones S. CM gingival hyperplasia associated with nifedipine. Br Dent J 1986: 160: 416-417.
80. Kapuar RN, Girgis S, Little, TM, Masotti R. Diphenylhydantoin induced gingival hyperplasia; its relationship to dose and serum level. Dev Med Child Neuron 1973: 15: 483-487.
81. Kimball O. The treatment of epilepsy with sodium dipenylhydantoinate. JAMA 1939: 112: 1244-1245.
82. King GN, Fullinfaw R, Higgins TS, Walker RJ, Francis DMA, Wiesenfeld D. Gingival hyperplasia in renal allograft recipients receiving cyclosporine A and calcium antagonists. J Clin Periodontol 1993: 20: 286-293.
83. Klintmalm GBG, Iwatsuki S. Nephrotoxicity of cyclosporine A in liver and kidney transplant patients. Lancet 1981: 4: 470-471.
84. Lainson PA. Gingival overgrowth in a patient treated with nifedipine (Procardia). Periodontal Case Rep 1986: 8: 14-16.
85. Lederman D, Lumerman H, Reuben S, Freedman PD. Gingival hyperplasia associated with nifedipine therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1984: 57: 620-622.
86. Leppik IE. Anti-epileptic medications. Compendium Contin Educ Dent 1990: 11(suppl 14): S490-S496.
87. Lewis JG. Adverse reactions to calcium antagonists. Drugs 1983: 25: 196-222.
88. Liu TZ, Bhatnegar RS. Inhibition of protocollagen prolive hydroxylases by Dilantin®. Proc Soc Exp Biol Med 1973: 42: 253-255.
89. Livingston S, Livingstone H. Diphenylhydantoin gingival hyperplasia. Am J Dis Child 1969: 117: 265-270.
90. Livingston S. The medical treatment for epilepsy: Managing side-effects of anti-epileptic drugs. Pediatr Ann 1970: 8: 261-266.
91. Löe H, Theilade E, Jensen S. Experimental gingivitis in man. J Periodontol 1965: 36: 177-187.
92. Lombardi T, Fiore-Donno G, Belser U, Dia Felice R. Felodipine-induced gingival hyperplasia: a clinical and histologie study. J Oral Pathol Med 1991: 20: 89-92.
93. Lucas RM, Howell LP, Wall BA. Nifedipine-induced gingival hyperplasia. J Periodontol 1985: 56: 211-215.
94. Lundergan WP. Drug-induced gingival enlargements. J Can Dent Assoc 1989: 17: 48-52.
95. Mallek HM, Nakamoto T. Dilantin and folic acid. J Periodontol 1981: 52: 255-259.
96. Mariani G, Calastrini C, Carinci F, Marzola R, Calura G. Ultrastructural features of cyclosporine A-induced gingival hyperplasia. J Periodontol 1993: 64: 1092-1097.
97. Mariani G, Calastrini C, Carinci F, Bergamini L, Calastrini F, Stabellini G. Ultrastructural and histochemical features of the ground substance in cyclosporine A-induced gingival overgrowth. J Periodontol 1996: 67: 21-27.
98. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Behcet's disease. Lancet 1989: 12: 1093-1096.
99. McGaw T, Lam S, Coates J. Cyclosporine-induced gingival overgrowth: correlation with dental plaque scores, gingivitis scores and cyclosporine levels in serum and saliva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1987: 64: 293-297.
100. McKevitt KM, Irwin CR. Phenotypic differences in growth, matrix synthesis and response to nifedipine between fibroblasts derived form clinically healthy and overgrown gingival tissue. J Oral Pathol Med 1995: 24: 66-71.
101. Mehta A. Verapamil-induced gingival hyperplasia in children. Am Heart J 1992: 124: 535-536.
102. Merritt H, Putnam T. Sodium diphenyhydantoinate in the treatment of convulsive disorders. JAMA 1938: 111: 1068-1073.
103. Miller CS, Damm DD. Incidence of verapamil-induced gingival hyperplasia in a dental population. J Periodontol 1992: 63: 453-456.
104. Modéer T, Dahllöf G. Development of phenytoin-induced gingival overgrowth in non-institutionalized epileptic children subjected to different plaque control programs. Acta Odontol Scand 1987: 45: 81-85.
105. Modéer T, Mendez C, Dahllöf G, Auduren I, Andersson G. Effect of phenytoin medication on the metabolism of epidermal growth factor receptor in cultured gingival fibroblasts. J Periodontal Res 1990: 25: 120-127.
106. Moy LS, Tan EML, Holness R, Uitte J. Phenytoin modulates connective tissue metabolism and cell proliferation in human skin fibroblasts culture. Dermatology 1985: 121: 79-83.
107. Muller W, Herrmann B. Cyclosporine A for psoriasis. N Engl J Med 1979: 301: 355.
108. Nally FF. Gingival hyperplasia due to primidone (Mysoline®) - case report. J Ir Dent Assoc 1967: 13(5): 113-114.
109. Nares S, Ng MC, Dill RE, Park B, Cutler CW, Iacopino AM. Cyclosporine A upregulates platelet-derived growth factor B chain in hyperplastic human gingiva. J Periodontol 1996: 67: 271-278.
110. Narayanan A, Meyers D, Page R. Regulation of collagen production in fibroblasts cultured from normal and phenytoin-induced hyperplastic gingiva. J Periodontal Res 1988: 23: 118-121.
111. Nery EB, Edson RG, Lee KK, Pruthi VJ, Watson J. Prevalence of nifedipine-induced gingival hyperplasia. J Periodontol 1995: 66: 572-578.
112. Niimi A, Tohnai I, Kaneda T, Takeuchi M, Nagura H. Immunohistochemical analysis of effects of cyclosporine A on gingival epithelium. J Oral Pathol Med 1990: 19: 397-403.
113. Nishikawa S, Tada H, Hamasaki A, Kasahara S, Kido J, Nagata T, Ishida H, Wakano Y. Nifedipine-induced gingival hyperplasia: a clinical and in vitro study. J Periodontol 1991: 62: 30-35.
114. Nishikawa S, Nagata T, Morisake I, Oka T, Ishida H. Pathogenesis of drug-induced gingival overgrowth. A review of studies in the rat model. J Periodontol 1996: 67: 463-471.
115. Nursing 97 drug handbook. Springhouse, PA: Springhouse Corporation, 1997: 232-296.
116. Nussenblatt RB, Palestine AG, Chan C, Mochizuki M, Yancey K. Effectiveness of cyclosporine therapy for Behçet's disease. Arthritis Rheum 1985: 28: 671-679.
117. Nyska A, Waner T, Pirak M, Galiano A, Zlotogorski A. Gingival hyperplasia in rats induced by oxodipine, a new calcium channel blocker. J Periodontal Res 1990: 25: 65-68.
118. O'Neil TCA, Figures KH. The effects of chlorhexidine and mechanical method of plaque control on recurrence of gingival hyperplasia in young patients taking phenytoin. Br Dent J 1982: 152: 130-133.
119. O'Valle F, Mesa F, Aneiros J, Gomez-Morales M, Lucena MA, Ramirez C, Revelles F, Moreno E, Navarro N, Caballero T, Masseroli M, Garcia del Moral R. Gingival overgrowth induced by nifedipine and cyclosporine A. J Clin Periodontol 1995: 22: 591-597.
120. Pagliarini A, Stabellini G, Carinci F, Calura G, Tognon M, Evangelisti R. Heterogenicity of fibroblasts derived from human free and attached gingiva. Glycoaminoglycan synthesis and effects of phenytoin (PHT) treatment. J Oral Pathol Med 1995: 24: 72-77.
121. Peñarrocha-Diago M, Bagán-Sebastián J, Vera-Sempere F. Dipenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study. J Periodontol 1990: 61: 571-574.
122. Pernu HE, Knuuttila MLE, Huttenen KRH, Tiilikainen ASK. Drug-induced gingival overgrowth and class II major histocompatibility antigens. Transplantation 1994: 57: 1811-1813.
123. Pernu H, Oikarinen K, Hietanen J, Knuuttila M. Verapamil-induced gingival overgrowth: a clinical, histologic and biochemical approach. J Oral Med Pathol 1989: 18: 422-425.
124. Pernu HE, Pernu LMH, Huttunen KRH, Nieminen PA, Knuuttila MLE. Gingival overgrowth among renal transplant patients related to immunosuppressive medication and possible local background factors. J Periodontol 1992: 63: 548-553.
125. Pernu HE, Pernu LMH, Knuuttila MLE. Effect of periodontal treatment on gingival overgrowth among cyclosporine A treated renal transplant recipients. J Periodontol 1993: 64: 1098-1100.
126. Physician's desk reference. 51st edn. Montvale, NJ: Medical Economics Company, 1997.
127. Pihlstrom BL. Prevention and treatment of Dilantin®-associated gingival enlargment. Compendium Contin Educ Dent 1990: 11(suppl 14): S506-S510.
128. Pihlstrom BL, Carlson JF, Smith QT, Bautien SA, Keenan KM. Prevention of phenytoin-associated gingival enlargement - a 15-month longitudinal study. J Periodontol 1980: 51: 311-317.
129. Pisanty S, Shoshan S, Chajek T, Maftsir G, Scks B, Benezra D. The effect of cyclosporine A (CsA) treatment on gingival tissue of patients with Behçet's disease. J Periodontol 1988: 59: 599-603.
130. Plemons JM, Dill RE, Rees TD, Dyer BJ, Ng MC, Iacopino AM. PDGF-B producing cells and PDGF-B gene expression in normal gingiva and cyclosporine A-induced gingival overgrowth. J Periodontol 1996: 67: 264-270.
131. Poppell TD, Keeling SD, Collins JF, Hassell TM. Effect of folic acid on recurrence of phenytoin-induced gingival overgrowth following gingivectomy. J Clin Periodontol 1991: 18: 134-139.
132. Powles RL, Clink HM, Spence D, Morgenstern G, Watson JG, Selby PJ, Woods M, Barrett A, Jameson B, Sloan J, Lawler SD, Kay HEM, Lawson D, Mcelwait TJ, Alexander P. Cyclosporine A to prevent graft-vs-host disease in man after allogeneic bone marrow transplantation. Lancet 1980: 3: 327-239.
133. Puolijoki H, Siitonen L, Saha H, Suojanen I. Gingival hyperplasia caused by nifedipine. Proc Finn Dent Soc 1988: 84: 311-314.
134. Ramon Y, Behar S, Kishon Y, Engelberg I. Gingival hyperplasia caused by nifedipine - a preliminary report. Int J Cardiol 1984: 5: 195-206.
135. Rams TE, Keyes PH. Regression of gingival hyperplasia after cessation of phenytoin drug therapy - a case report. Quintessence Int 1984: 5: 539-544.
136. Rateitschak-Plüss EM, Hefti A, Lortscher R, Thiel G. Initial observation that cyclosporine A induces gingival enlargement in man. J Clin Periodontol 1983: 10: 237-246.
137. Rebuck AS, Stiller CR, Braude AC, Laupacis A, Cohen RD, Chapman KR. Cyclosporine for pulmonary sarcoidosis. Lancet 1984: 7: 1174.
138. Rees TD. Drugs and the periodontium. In: Newman AN, Rees TD, Kinane DF, ed. Diseases of the periodontium. Northwood, England: Science Reviews Limited, 1993: 109-134.
139. Rees TD, Levine RA. Systemic drugs as a risk factor for periodontal disease initiation and progression. Compendium Contin Educ Dent 1995: 16(11): 20-41.
140. Reynolds NC, Kirkham DB. Therapeutic alternatives in phenytoin-induced gingival hyperplasia. A case report and discussion. J Periodontol 1980: 51: 516-520.
141. 2 laser gingivectomy for phenytoin-induced gingival hyperplasia in mentally retarded patients. J Clin Periodontol 1993: 20: 279.
142. Rossmann JA, Ingles E, Brown RS. Mutimodal treatment of drug-induced gingival hyperplasia in a kidney transplant patient. Compendium Contin Educ Dent 1994: 15: 1266-1274.
143. Rostock MH, Fry HR, Turner JE. Severe gingival overgrowth associated with cyclosporine therapy. J Periodontol 1986: 57: 294-299.
144. Royer JE, Hendrickson DA, Scharpf HO. Phenytoin-induced hyperplasia of the pre-eruptive stage. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1983: 56: 365-367.
145. Russell BG, Bay LM. Oral use of chlorhexidine gluconate toothpaste in epileptic children. Scand J Dent Res 1978: 86: 52-57.
146. Schincaglia GP, Fornit F, Cavallini R, Piva R, Calura G, Del Senno L. Cyclosporine A increases type I procollagen production and mRNA level in human gingival fibroblasts in vitro. J Oral Pathol Med 1992: 21: 181-185.
147. Schulz A, Lange DE, Hassell TM, Stone CE, Lison AE. Cyclosporine-induced gingival hyperplasia in renal transplant patients. Dtsch Zahnärztl Z 1990: 45: 414-416.
148. Seymour RA. Calcium channel blockers and gingival overgrowth. Br Dent J 1991: 170: 376-379.
149. Seymour RA, Ellis JS, Thomason JM, Monkman S, Idle JR. Amlodipine-induced gingival overgrowth. J Clin Periodontol 1994: 21: 281-283.
150. Seymour R, Heasman P. Drugs and the periodontium. J Clin Periodontol 1988: 15: 1-16.
151. Seymour RA, Jacobs DJ. Cyclosporine and the gingival tissues. J Clin Periodontol 1992: 19: 1-11.
152. Seymour RA, Smith DG, Rogers SR. The comparative effects of azathioprine and cyclosporine on some gingival health parameters of renal transplant patients. A longitudinal study. J Clin Periodontol 1987: 14: 610-613.
153. Seymour RA, Smith DC, Turnbull DN. The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients. J Clin Periodontol 1985: 12: 413-419.
154. Seymour RA, Thomason JM, Ellis JS. The pathogenesis of drug-induced gingival overgrowth. J Clin Periodontol 1996: 23: 165-175.
155. Shafer WG. Effect of dilantin sodium analogues on cell proliferation in tissue culture. Proc Soc Exp Biol Med 1960: 106: 205-207.
156. Shibley O, Ciancio S, Adnerson T, Bartz N, Mather M, Farber R. The role of 0.12% chlorhexidine gluconate in drug-induced hyperplasia. J Dent Res 1994: 73: 356 (abstr 2034).
157. Silverstein LH, Koch JP, Lefkove MD, Garnick JJ, Singh B, Steflik DE. Nifedipine-induced gingival enlargement around dental implants: a clinical report. J Oral Implantol 1995: 21: 116-120.
158. Slavin J, Taylor J. Cyclosporine, nifedipine and gingival hyperplasia. Lancet 1987: 10: 739.
159. Somacarrera ML, Hernandez G, Acero J, Moskow BS. Factors related to the incidence and severity of cyclosporine-induced gingival overgrowth in transplant patients. A longitudinal study. J Periodontol 1994: 65: 671-675.
160. Starzl TE, Weil R, Iwatsuki S, Klintmalm G, Schroter GPJ, Koep LJ, Iwaki Y, Terasaki PI, Porter KA. The use of cyclosporine A and prednisone in cadaver kidney transplan-tation. Surg Gynecol Obstet 1980: 151: 17-26.
161. Steele RM, Schuna AA, Schreiber RT. Calcium antagonist-induced gingival hyperplasia. Ann Intern Med 1994: 120: 663-664.
162. Steinberg AD. Office management of phenytoin-induced gingival overgrowth. Compendium Contin Educ Dent 1985: 6: 138-147.
163. Stiller CR, Laupacis A, Dupre J, Jenner MR, Keown PA, Rodger W, Wolfe BMJ. Cyclosporine for treatment of early type I diabetes: preliminary results. N Engl J Med 1983: 308: 1226-1227.
164. Stinnett E, Rodu B, Grizzle WE. New developments in understanding phenytoin-induced gingival hyperplasia. JAMA 1987: 114: 814-816.
165. Syrjänen SM, Syrjänen KJ. Hyperplastic gingivitis in a child receiving sodium valproate treatment. Proc Finn Dent Soc 1979: 75: 95-98.
166. Tagawa T, Nakamura H, Murata M. Marked gingival hyperplasia induced by nifedipine. Int J Oral Maxillofac Surg 1989: 19: 72-73.
167. Tal H, Littner S, Gordon M. Effect of oral hygiene on phenytoin-induced gingival hyperplasia. Dent Med 1988: 6: 10-13.
168. The Medical Letter. Amlodipine - a new calcium-channel blocker. 1992: 34: 99-100.
169. The Medical Letter. Felodipine - another calcium-channel blocker for hypertension. 1991: 33: 115-116.
170. Thivolet J, Barthelemy H, Rigot-Muller G, Bendelac A. Effects of cyclosporine on bullous pemphigoid and pemphigus. Lancet 1985: 8: 334-335.
171. Thomason JM, Seymour RA, Ellis JS, Kelly PJ, Parry G, Dark J, Idle JR. Iatrogenic gingival overgrowth in cardiac transplantation. J Periodontol 1995: 66: 742-746.
172. Thomason JM, Seymour RA, Rawlings MD. Incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients in general medical practice. Community Dent Oral Epidemiol 1992: 20: 288-291.
173. Thomason JM, Seymour RA, Rice N. The prevalence and severity of cyclosporine and nifedipine-induced gingival overgrowth. J Clin Periodontol 1993: 20: 37-40.
174. Tigaran S. A 15-year followup of phenytoin-induced unilateral gingival hyperplasia: a case report. Acta Neurol Scand 1994: 90: 367-370.
175. Tipton DA, Stricklin GP, Dabbous MK. Fibroblast heterogeneity of collagenolytic response to cyclosporine. J Cell Biochem 1991: 46: 152-165.
176. Tyldesley WR, Rotter E. Gingival hyperplasia induced by cyclosporine A. Br Dent J 1984: 157: 305-309.
177. Van der Wall EE, Tuinzing DB, Hes J. Gingival hyperplasia induced by nifedipine, an arterial vasodilating drug. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1985: 60: 38-40.
178. Vernillo AT, Schwartz NB. The effects of phenytoin (5,5-diphenylhydantoin) on human gingival fibroblasts in culture. J Periodontal Res 1987: 22: 307-312.
179. Vijayasingham SM, Dykes PJ, Marks R. Phenytoin has little effect on in vitro models of wound healing. Br J Dermatol 1991: 125: 136-139.
180. Waner T, Nyska A, Nyska M, Sela M, Pirak M, Galiano A. Gingival hyperplasia in dogs induced by oxodipine, a calcium channel blocker. Toxicol Pathol 1988: 16: 327-332.
181. Westbrook P, Bednarczyk E, Carlson M, Sheehan H, Bissada N. Regression of nifedipine-induced gingival hyperplasia following switch to a same class calcium channel blocker, isradipine. J Periodontol 1997: 68: 645-650.
182. Wilson TG, Kornman KS. Fundamentals of periodontics. Carol Stream, IL: Quintessence Publishing Co., 1996: 263-265.
183. Wynn RL. Calcium channel blockers and gingival hyperplasia. Gen Dent 1991: 39: 240-243.
184. Wysocki GP, Gretzinger HA, Laupacis A, Ulan RA, Stiller CR. Fibrous hyperplasia of the gingiva: a side effect of cyclosporine A therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1983: 55: 274-278.
185. 3-glucosamine by fibroblast populations exposed to cyclosporine. J Periodontol 1994: 65: 565-567.